BioCentury
ARTICLE | Company News

SciClone deal

November 18, 2016 9:31 PM UTC

SciClone received an unsolicited bid from a consortium led by ABM Management Ltd. and GL Capital Management GP Ltd. to acquire all outstanding shares not already owned for $11.18 per share in cash. The price is a 13.5% premium to SciClone’s close of $9.85 on Nov. 11, before the bid was announced. The consortium said the remaining portion of the company will cost about $546 million...